{"product_id":"anticancer-therapeutics-9780470723036","title":"Anticancer Therapeutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten by the winner of the 2008 Mike Price Fellowship  The need to re-address known anti-cancer agents and discover new ones are of paramount importance. Anticancer Therapeutics  provides a comprehensive overview of the wealth of information currently available on this important and fast-moving subject.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e“This book is very well conceived and well presented.” (\u003ci\u003eDoody's Reviews\u003c\/i\u003e, June 2009)  \u003cp\u003e\"This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject.\" (\u003ci\u003eAnticancer Research\u003c\/i\u003e, November - December 2008)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eForward xiii\u003c\/p\u003e \u003cp\u003eAcknowledgements xv\u003c\/p\u003e \u003cp\u003eList of contributors xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Development of Anticancer Therapeutics 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Exploring the Potential of Natural Products in Cancer Treatment 3\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFotini N. Lamari and Paul Cordopatis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 3\u003c\/p\u003e \u003cp\u003e1.2 Sources 4\u003c\/p\u003e \u003cp\u003e1.3 Different Approaches to the Search for Bioactive Natural Products 6\u003c\/p\u003e \u003cp\u003e1.4 Methodologies of Lead Compound or New Drug Identification 10\u003c\/p\u003e \u003cp\u003e1.5 Chemoprevention – A New Area for Natural Product Research 13\u003c\/p\u003e \u003cp\u003e1.6 Concluding Remarks 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Combinatorial Approaches to Anticancer Drug Design 17\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 17\u003c\/p\u003e \u003cp\u003e2.2 Combinatorial Approaches for Small Molecule Drug Design 17\u003c\/p\u003e \u003cp\u003e2.3 Display Technologies 21\u003c\/p\u003e \u003cp\u003e2.4 Aptamer Selection 23\u003c\/p\u003e \u003cp\u003e2.5 Conclusions 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Rational Approaches to Anticancer Drug Design\/in silico Drug Development 29\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStefano Alcaro, Anna Artese and Francesco Ortuso\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 29\u003c\/p\u003e \u003cp\u003e3.2 Approaches to the Drug Discovery Process in Anticancer Research 31\u003c\/p\u003e \u003cp\u003e3.3 Ligand-based Examples 32\u003c\/p\u003e \u003cp\u003e3.4 Structure-based Examples 36\u003c\/p\u003e \u003cp\u003e3.5 Conclusions 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Anticancer Therapeutics 47\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Introduction to Anticancer Therapeutics 49\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Problems in cancer 49\u003c\/p\u003e \u003cp\u003e4.2 Cancer treatments 51\u003c\/p\u003e \u003cp\u003e4.3 Classification of chemotherapy drugs 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Platinum Drugs 55\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas, Alexandros Pantos, Evagelos Bellis and Petros Christofis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Cisplatin 55\u003c\/p\u003e \u003cp\u003e5.2 Lipoplatin 57\u003c\/p\u003e \u003cp\u003e5.3 Carboplatin 61\u003c\/p\u003e \u003cp\u003e5.4 Oxaliplatin 62\u003c\/p\u003e \u003cp\u003e5.5 Lipoxal 62\u003c\/p\u003e \u003cp\u003e5.6 New Platinum Compounds 64\u003c\/p\u003e \u003cp\u003e5.7 Cisplatin Resistance and Chemotherapy 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Antimicrotubule Agents 79\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIain Brown, Jay N Sangrithi-Wallace and Andrew C Schofield\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Taxanes 79\u003c\/p\u003e \u003cp\u003e6.2 Vinca Alkaloids 82\u003c\/p\u003e \u003cp\u003e6.3 Mechanisms of Resistance to Antimicrotubule Agents 86\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Antimetabolites in Cancer Therapy 91\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJessica Scaife and David Kerr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 91\u003c\/p\u003e \u003cp\u003e7.2 Folate Antagonists 92\u003c\/p\u003e \u003cp\u003e7.3 Pyrimidine Antagonists 96\u003c\/p\u003e \u003cp\u003e7.4 Purine Antagonists 104\u003c\/p\u003e \u003cp\u003e7.5 Summary 109\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Antitumour Antibiotics 111\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eManuel M. Paz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 111\u003c\/p\u003e \u003cp\u003e8.2 Actinomycin 111\u003c\/p\u003e \u003cp\u003e8.3 Mitomycin c 112\u003c\/p\u003e \u003cp\u003e8.4 Bleomycin 115\u003c\/p\u003e \u003cp\u003e8.5 Anthracyclines 118\u003c\/p\u003e \u003cp\u003e8.6 Trabectedin (Ecteinascidin, ET-743) 121\u003c\/p\u003e \u003cp\u003e8.7 Camptothecins 123\u003c\/p\u003e \u003cp\u003e8.8 Podophyllotoxins 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Alkylating Agents 133\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAna Paula Francisco, Maria de Jesus Perry, Rui Moreira and Eduarda Mendes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 133\u003c\/p\u003e \u003cp\u003e9.2 Nitrogen Mustards 133\u003c\/p\u003e \u003cp\u003e9.3 Methylmelamines and Ethylenimines 140\u003c\/p\u003e \u003cp\u003e9.4 Methylhydrazine Derivatives 141\u003c\/p\u003e \u003cp\u003e9.5 Alkylsulfonates 143\u003c\/p\u003e \u003cp\u003e9.6 Nitrosoureas 144\u003c\/p\u003e \u003cp\u003e9.7 Triazenes 149\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Hormone Therapies 159\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGeorge C. Zografos, Nikolaos V. Michalopoulos and Flora Zagouri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 159\u003c\/p\u003e \u003cp\u003e10.2 Oestrogen Receptor Targeted Therapeutics 160\u003c\/p\u003e \u003cp\u003e10.3 Progesterone-Targeted Therapy 174\u003c\/p\u003e \u003cp\u003e10.4 Neuroendocrine Tumours 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Photodynamic Therapy of Cancer 187\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eK. Eszter Borbas and Dorothée Lahaye\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 187\u003c\/p\u003e \u003cp\u003e11.2 Photosensitizers 196\u003c\/p\u003e \u003cp\u003e11.3 Outlook 212\u003c\/p\u003e \u003cp\u003e11.4 Acknowledgement 212\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Target-directed Drug Discovery 223\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTracey D. Bradshaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 223\u003c\/p\u003e \u003cp\u003e12.2 Tyrosine Kinases – Role and Significance in Cancer 226\u003c\/p\u003e \u003cp\u003e12.3 Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC) 226\u003c\/p\u003e \u003cp\u003e12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia 229\u003c\/p\u003e \u003cp\u003e12.5 Targeted Therapy for the Treatment of Breast Cancer 230\u003c\/p\u003e \u003cp\u003e12.6 Angiogenesis 231\u003c\/p\u003e \u003cp\u003e12.7 Targeting Cell Cycling 235\u003c\/p\u003e \u003cp\u003e12.8 Targeting Apoptosis 237\u003c\/p\u003e \u003cp\u003e12.9 Targeting mTOR 237\u003c\/p\u003e \u003cp\u003e12.10 The Future of Molecularly Targeted Therapy 238\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Tumour Hypoxia: Malignant Mediator 245\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJill L. O’Donnell, Aoife M. Shannon, David Bouchier-Hayes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 245\u003c\/p\u003e \u003cp\u003e13.2 Hypoxia Inducible Factor-1 and Hypoxia 246\u003c\/p\u003e \u003cp\u003e13.3 HIF-1α Post-translational Changes 247\u003c\/p\u003e \u003cp\u003e13.4 How Genetics Can Modify HIF 248\u003c\/p\u003e \u003cp\u003e13.5 How Tumours Overcome Hypoxia with HIF- 1 249\u003c\/p\u003e \u003cp\u003e13.6 HIF-1 Therapeutics 252\u003c\/p\u003e \u003cp\u003e13.7 Conclusion 255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Resistance to Chemotherapy Drugs 263\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRobert O’Connor and Laura Breen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 263\u003c\/p\u003e \u003cp\u003e14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment? 263\u003c\/p\u003e \u003cp\u003e14.3 A Classification of the Important Chemotherapy Resistance Mechanisms 265\u003c\/p\u003e \u003cp\u003e14.4 Illustrative Mechanisms of Pharmacokinetic Resistance 267\u003c\/p\u003e \u003cp\u003e14.5 Illustrative Mechanisms of Pharmacodynamic Resistance 273\u003c\/p\u003e \u003cp\u003e14.6 Conclusion 277\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Cancer Immunotherapy 283\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria Belimezi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 The Molecular Basis of Cancer Immunotherapy and Gene Immunotherapy of Cancer 283\u003c\/p\u003e \u003cp\u003e15.2 Recombinant Monoclonal Antibodies 284\u003c\/p\u003e \u003cp\u003e15.3 Cell Immunotherapy 292\u003c\/p\u003e \u003cp\u003e15.4 Cancer Vaccines 296\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Gene Therapy 305\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria Belimezi, Teni Boulikas and Michael L. Roberts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 The Concept of Gene Therapy 305\u003c\/p\u003e \u003cp\u003e16.2 Steps for Successful Gene Therapy 306\u003c\/p\u003e \u003cp\u003e16.3 Retroviruses in Cancer Gene Therapy 307\u003c\/p\u003e \u003cp\u003e16.4 Adenoviruses in Cancer Gene Therapy 308\u003c\/p\u003e \u003cp\u003e16.5 Gene Therapy of Cancer 310\u003c\/p\u003e \u003cp\u003e16.6 Cancer Immunotherapy with Cytokine Genes 311\u003c\/p\u003e \u003cp\u003e16.7 IL-12 in Cancer Immunotherapy 311\u003c\/p\u003e \u003cp\u003e16.8 Viruses able to Kill Cancer Cells 314\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Antisense Agents 317\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eHuma Khan and Sotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 317\u003c\/p\u003e \u003cp\u003e17.2 Traditional Antisense Oligonucleotides (ASOs) 318\u003c\/p\u003e \u003cp\u003e17.3 Ribozymes and DNAzymes 320\u003c\/p\u003e \u003cp\u003e17.4 RNA Interference and siRNAs 321\u003c\/p\u003e \u003cp\u003e17.5 Shortcomings of Antisense Therapeutics 322\u003c\/p\u003e \u003cp\u003e17.6 Antisense Agents in Clinical Trials 324\u003c\/p\u003e \u003cp\u003e17.7 Concluding Remarks 329\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Aptamers as Anticancer Agents 331\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eVaidehi Makwana, Suzanne Simmons and Sotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 331\u003c\/p\u003e \u003cp\u003e18.2 Aptamers in Cancer 332\u003c\/p\u003e \u003cp\u003e18.3 Final comments 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Other Aspects in Anticancer Therapeutic Development 347\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Treatment of Cancer in Conjunction with Other Agents 349\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGary Robert Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 349\u003c\/p\u003e \u003cp\u003e19.2 Non-steroidal Anti-inflammatory Drugs 353\u003c\/p\u003e \u003cp\u003e19.3 Angiotensin-converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockade 358\u003c\/p\u003e \u003cp\u003e19.4 Partners in Crime – Dealing with Co-infections 362\u003c\/p\u003e \u003cp\u003e19.5 Discussion 363\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Clinical Trials in Oncology 365\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTim Friede, Janet Dunn and Nigel Stallard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Clinical Trials 365\u003c\/p\u003e \u003cp\u003e20.2 Early-Phase (Phase I and Phase II) Clinical Trials in Oncology 368\u003c\/p\u003e \u003cp\u003e20.3 Confirmatory (Phase III) Trials in Oncology 371\u003c\/p\u003e \u003cp\u003e20.4 Further Issues in Clinical Trials in Oncology 374\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Representative Cancers, Treatment and Market 377\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTeni Boulikas and Nassos Alevizopoulos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Lung Cancer 377\u003c\/p\u003e \u003cp\u003e21.2 Breast Cancer 378\u003c\/p\u003e \u003cp\u003e21.3 Prostate Cancer 378\u003c\/p\u003e \u003cp\u003e21.4 Colorectal Cancer 379\u003c\/p\u003e \u003cp\u003e21.5 Ovarian Cancer 380\u003c\/p\u003e \u003cp\u003e21.6 Pancreatic Cancer 380\u003c\/p\u003e \u003cp\u003e21.7 Gastric Cancer 381\u003c\/p\u003e \u003cp\u003e21.8 Combination Chemotherapy 382\u003c\/p\u003e \u003cp\u003e21.9 The Pharmaceutical World of Anticancer Drugs 383\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Future Trends in Cancer Therapeutics 387\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSotiris Missailidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 387\u003c\/p\u003e \u003cp\u003e22.2 Personalized Medicines 388\u003c\/p\u003e \u003cp\u003e22.3 Delivery Systems 390\u003c\/p\u003e \u003cp\u003e22.4 Closing Remarks 391\u003c\/p\u003e \u003cp\u003eIndex 393\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":53515418861911,"sku":"9780470723036","price":138.56,"currency_code":"GBP","in_stock":true}],"url":"https:\/\/bookcurl.com\/products\/anticancer-therapeutics-9780470723036","provider":"Book Curl","version":"1.0","type":"link"}